What is Actuate Therapeutics Inc's earnings per share (EPS)?

Actuate Therapeutics Inc (ACTU) reported diluted earnings per share of $-1.06 for fiscal year 2025. This represents a 67.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Actuate Therapeutics Inc Financials

ACTU

Source SEC Filings (10-K/10-Q) Updated Mar 26, 2026 Currency USD FYE March

This page shows Actuate Therapeutics Inc (ACTU) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Actuate Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.86x

For every $1 of reported earnings, Actuate Therapeutics Inc generates $0.86 in operating cash flow (-$19.2M OCF vs -$22.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1110.9x

Actuate Therapeutics Inc earns $-1110.9 in operating income for every $1 of interest expense (-$22.5M vs $20K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$22.2M

YoY+18.5%

Actuate Therapeutics Inc reported -$22.2M in net income in fiscal year 2025. This represents an increase of 18.5% from the prior year.

EPS (Diluted)

$-1.06

YoY+67.5%

Actuate Therapeutics Inc earned $-1.06 per diluted share (EPS) in fiscal year 2025. This represents an increase of 67.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$13.2M

YoY+52.3%

Actuate Therapeutics Inc held $13.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

24M

YoY+21.4%

Actuate Therapeutics Inc had 24M shares outstanding in fiscal year 2025. This represents an increase of 21.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-280.5%

YoY+25908.5pp

Actuate Therapeutics Inc's ROE was -280.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 25908.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$10.3M

YoY-44.9%

Actuate Therapeutics Inc invested $10.3M in research and development in fiscal year 2025. This represents a decrease of 44.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ACTU Income Statement

Metric	FY25	FY24	FY23
Revenue	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	$10.3M-44.9%	$18.7M-14.0%	$21.7M
SG&A Expenses	$12.2M+88.2%	$6.5M+98.6%	$3.3M
Operating Income	-$22.5M+10.6%	-$25.2M-0.7%	-$25.0M
Interest Expense	$20K+8.2%	$19K-57.1%	$44K
Income Tax	$8000.0%	$800	$0
Net Income	-$22.2M+18.5%	-$27.3M-10.3%	-$24.7M
EPS (Diluted)	$-1.06+67.5%	$-3.26	$-17.24

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.2M-21.2%	$2.8M-14.1%	$3.2M	N/A	$3.8M-14.1%	$4.4M-36.3%	$6.9M	N/A
SG&A Expenses	$3.3M+2.8%	$3.2M+1.9%	$3.1M	N/A	$1.6M+53.9%	$1.1M+16.4%	$913K	N/A
Operating Income	-$5.5M+8.3%	-$6.0M+6.2%	-$6.4M	N/A	-$5.4M+0.8%	-$5.4M+30.1%	-$7.8M	N/A
Interest Expense	$5K0.0%	$5K0.0%	$5K	N/A	$3K-31.3%	$5K0.0%	$5K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.4M+9.1%	-$5.9M+5.8%	-$6.3M	N/A	-$6.0M+9.1%	-$6.6M+20.8%	-$8.3M	N/A
EPS (Diluted)	$-0.25+16.7%	$-0.30+6.3%	$-0.32	N/A	$-0.55	$-4.20+22.2%	$-5.40	N/A

ACTU Balance Sheet

Metric	FY25	FY24	FY23
Total Assets	$14.0M+50.6%	$9.3M+211.1%	$3.0M
Current Assets	$13.6M+48.2%	$9.2M+207.4%	$3.0M
Cash & Equivalents	$13.2M+52.3%	$8.6M+192.1%	$3.0M
Inventory	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	$6.1M-33.7%	$9.2M-91.0%	$102.6M
Current Liabilities	$5.7M-35.2%	$8.8M+27.2%	$6.9M
Long-Term Debt	N/A	N/A	N/A
Total Equity	$7.9M+7505.6%	$104K+100.1%	-$99.6M
Retained Earnings	-$154.6M-16.8%	-$132.4M-26.0%	-$105.1M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$17.7M+154.2%	$7.0M+55.5%	$4.5M-51.9%	$9.3M-34.7%	$14.3M+724.0%	$1.7M	N/A	$3.0M
Current Assets	$17.4M+160.8%	$6.7M+57.4%	$4.2M-53.9%	$9.2M-35.4%	$14.3M+2494.7%	$550K	N/A	$3.0M
Cash & Equivalents	$16.9M+160.7%	$6.5M+66.9%	$3.9M-55.0%	$8.6M-36.1%	$13.5M+3745.1%	$352K-83.0%	$2.1M-30.1%	$3.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.8M-29.6%	$9.6M+0.5%	$9.6M+3.9%	$9.2M+3.5%	$8.9M-92.3%	$116.0M	N/A	$102.6M
Current Liabilities	$6.4M-30.7%	$9.2M+0.5%	$9.2M+4.0%	$8.8M+3.6%	$8.5M-57.7%	$20.1M	N/A	$6.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$10.9M+512.1%	-$2.7M+47.8%	-$5.1M-4983.3%	$104K-98.1%	$5.4M+104.7%	-$114.3M-6.0%	-$107.8M-8.2%	-$99.6M
Retained Earnings	-$150.1M-3.7%	-$144.6M-4.3%	-$138.7M-4.8%	-$132.4M-5.1%	-$125.9M-5.0%	-$120.0M	N/A	-$105.1M

ACTU Cash Flow Statement

Metric	FY25	FY24	FY23
Operating Cash Flow	-$19.2M+12.1%	-$21.8M-1.0%	-$21.6M
Capital Expenditures	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A
Financing Cash Flow	$23.7M-13.8%	$27.5M+565.8%	$4.1M
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$6.7M-60.0%	-$4.2M+9.6%	-$4.6M+3.2%	-$4.8M+47.8%	-$9.1M-242.2%	-$2.7M+49.1%	-$5.2M+4.8%	-$5.5M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$17.1M+152.5%	$6.8M+5177.3%	-$133K-22.0%	-$109K-100.5%	$22.3M+2232.3%	$957K-78.0%	$4.4M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ACTU Financial Ratios

Metric	FY25	FY24	FY23
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A
Return on Equity	-280.5%+25908.5pp	-26189.0%	N/A
Return on Assets	-158.4%+134.5pp	-292.8%+533.2pp	-826.0%
Current Ratio	2.39+1.3	1.05+0.6	0.43
Debt-to-Equity	0.77-87.7	88.44+89.5	-1.03
FCF Margin	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-49.5%	N/A	N/A	N/A	-111.4%	N/A	N/A	N/A
Return on Assets	-30.5%+54.8pp	-85.4%+55.5pp	-140.9%	N/A	-41.9%+337.9pp	-379.7%	N/A	N/A
Current Ratio	2.74+2.0	0.73+0.3	0.46-0.6	1.05-0.6	1.68+1.7	0.03	N/A	0.43
Debt-to-Equity	0.62+4.2	-3.63-1.7	-1.88-90.3	88.44+86.8	1.66+2.7	-1.02	N/A	-1.03
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Cardiff Oncology Inc CRDF

$110.1M

Nuvectis Pharma, Inc. NVCT

$201.3M

Greenwich Lifesciences Inc GLSI

$318.1M

Avalo Therapeutics Inc AVTX

$380.6M

Oncolytics Biotech Inc ONCY

$100.1M

Frequently Asked Questions

Is Actuate Therapeutics Inc profitable?

No, Actuate Therapeutics Inc (ACTU) reported a net income of -$22.2M in fiscal year 2025.

What is Actuate Therapeutics Inc's return on equity (ROE)?

Actuate Therapeutics Inc (ACTU) has a return on equity of -280.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Actuate Therapeutics Inc's operating cash flow?

Actuate Therapeutics Inc (ACTU) generated -$19.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Actuate Therapeutics Inc's total assets?

Actuate Therapeutics Inc (ACTU) had $14.0M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Actuate Therapeutics Inc spend on research and development?

Actuate Therapeutics Inc (ACTU) invested $10.3M in research and development during fiscal year 2025.

How many shares does Actuate Therapeutics Inc have outstanding?

Actuate Therapeutics Inc (ACTU) had 24M shares outstanding as of fiscal year 2025.

What is Actuate Therapeutics Inc's current ratio?

Actuate Therapeutics Inc (ACTU) had a current ratio of 2.39 as of fiscal year 2025, which is generally considered healthy.

What is Actuate Therapeutics Inc's debt-to-equity ratio?

Actuate Therapeutics Inc (ACTU) had a debt-to-equity ratio of 0.77 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Actuate Therapeutics Inc's return on assets (ROA)?

Actuate Therapeutics Inc (ACTU) had a return on assets of -158.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Actuate Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Actuate Therapeutics Inc (ACTU) had $13.2M in cash against an annual operating cash burn of $19.2M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Actuate Therapeutics Inc's Piotroski F-Score?

Actuate Therapeutics Inc (ACTU) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Actuate Therapeutics Inc's earnings high quality?

Actuate Therapeutics Inc (ACTU) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Actuate Therapeutics Inc cover its interest payments?

Actuate Therapeutics Inc (ACTU) has an interest coverage ratio of -1110.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.